Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 243-249

  Nikanjam, M ^a   Chadwick, E G ^b   Robbins, B ^c   Alvero, C ^d   Palumbo, P ^e   Yogev, R ^b   Pinto, J ^f   Hazra, R ^g   Hughes, M L ^d   Heckman, B E ^h   Capparelli, E V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CHILD DEVELOPMENT; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; FEMALE; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MATURATION; MONTE CARLO METHOD; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE;

CHILD DEVELOPMENT; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOPINAVIR; MALE; RITONAVIR;

EID: 84855962333     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.218     Document Type: Article

References (29)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS Epidemic Update: December 2010 〈http://www. unaids.org/globalreport/Epi-slides.htm.
2. Nolan, M., Fowler, M.G. & Mofenson, L.M. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J. Acquir. Immune Defic. Syndr. 30, 216-229 (2002). (Pubitemid 34664419)
3. Palumbo, P. et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N. Engl. J. Med. 363, 1510-1520 (2010).
4. Jaspan, H.B., Lawn, S.D., Safrit, J.T. & Bekker, L.G. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 20, 483-494 (2006). (Pubitemid 43731592)
5. Milsap, R.L. & Jusko, W.J. Pharmacokinetics in the infant. Environ. Health Perspect. 102(suppl. 11), 107-110 (1994).
6. Winstanley, P.A. & Orme, M.L. The effects of food on drug bioavailability. Br. J. Clin. Pharmacol. 28, 621-628 (1989). (Pubitemid 20003947)
7. Chadwick, E.G. et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 22, 249-255 (2008).
8. Chadwick, E.G. et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr. Infect. Dis. J. 28, 215-219 (2009).
9. Chadwick, E.G. et al. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS 25, 643-649 (2011).
10. Summary of WHO pediatric antiretroviral therapy dosing: Annex E 〈http://www.who.int/hiv/paediatric/Sum-WHO-ARV-Ped-ARV-dosing.pdf.
11. Murphy, R.L. et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15, F1-F9 (2001). (Pubitemid 32055772)
12. Rowland, M. & Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. (Lippincott Williams and Wilkins, Philadelphia, PA, 1995).
13. Chandwani, A. & Shuter, J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther. Clin. Risk Manag. 4, 1023-1033 (2008).
14. Síz-Llorens, X. et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 22, 216-224 (2003).
15. Chadwick, E.G. et al. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr. Infect. Dis. J. 24, 793-800 (2005). (Pubitemid 41324888)
16. Jullien, V. et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob. Agents Chemother. 50, 3548-3555 (2006). (Pubitemid 44684864)
17. Rakhmanina, N., van den Anker, J., Baghdassarian, A., Soldin, S., Williams, K. & Neely, M.N. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. 53, 2532-2538 (2009).
18. Crommentuyn, K.M. et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol. 60, 378-389 (2005). (Pubitemid 41428469)
19. Dailly, E., Allavena, C., Raffi, F. & Jolliet, P. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. Br. J. Clin. Pharmacol. 60, 32-34 (2005). (Pubitemid 40942778)
20. Dailly, E., Gagnieu, M.C., Allavena, C., Raffi, F. & Jolliet, P. No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach. Ther. Drug Monit. 27, 782-784 (2005). (Pubitemid 44391735)
21. Dailly, E., Reliquet, V., Raffi, F. & Jolliet, P. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients. Eur. J. Clin. Pharmacol. 61, 153-156 (2005). (Pubitemid 40674748)
22. Bouillon-Pichault, M. et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J. Antimicrob. Chemother. 63, 1223-1232 (2009).
23. Molt J. et al. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin. Pharmacokinet. 47, 681-692 (2008).
24. Verweel, G. et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir. Ther. (Lond.) 12, 453-458 (2007). (Pubitemid 47044809)
25. Walmsley, S. et al.; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346, 2039-2046 (2002). (Pubitemid 34680595)
26. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 359, 733-740 (2002).
27. Moolasart, P. & Likanonsakul, S. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children. Southeast Asian J. Trop. Med. Public Health 33, 280-287 (2002).
28. A nderson, B.J., Allegaert, K. & Holford, N.H. Population clinical pharmacology of children: general principles. Eur. J. Pediatr. 165, 741-746 (2006). (Pubitemid 44440510)
29. Y en-Lieberman, B. et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J. Clin. Microbiol. 34, 2695-2701 (1996). (Pubitemid 26346488)